Clinical resistance encountered in the Respiratory Surveillance Program (RESP) study: A review of the implications for the treatment of community-acquired respiratory tract infections

American Journal of Medicine

Volumn 111, Issue 9 SUPPL. 1, 2001, Pages 30-35

  Ehrhardt, Anton F ^a   Russo, René ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFTRIAXONE; COTRIMOXAZOLE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; FREQUENCY MODULATION; HAEMOPHILUS INFLUENZAE; HEALTH SURVEY; HUMAN; MEDICAL PRACTICE; MORAXELLA CATARRHALIS; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REDUCTION; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0035905552     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(01)01029-4     Document Type: Review

References (62)

1. Practice guidelines for the management of community-acquired pneumonia in adults
2. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States
3. Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group
4. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae
5. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
6. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
7. The North American component (the United States and Canada) of an international comparative MIC trial monitoring ofloxacin resistance
8. The antimicrobial activity of cefotaxime: Comparative multinational hospital isolate surveys covering 15 years
9. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program
10. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
11. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
12. Epidemiology and sensitivity of 8625 ICU and hematology/oncology bacterial isolates in Europe
13. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System
14. National Nosocomial Infections Surveillance (NNIS) semiannual report, May 1995. A report from the National Nosocomial Infections Surveillance (NNIS) System
15. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: A report from the National Nosocomial Infections Surveillance (NNIS) System
16. Nosocomial infection rates for interhospital comparison: Limitations and possible solutions. A report from the National Nosocomial Infections Surveillance (NNIS) System
17. Nosocomial infections in surgical patients in the United States, January 1986-June 1992
18. Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections
19. Community-acquired pneumonia: Epidemiology, etiology, treatment
20. Epidemiology and treatment of chronic bronchitis and its exacerbations
21. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio
22. Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia
23. Impact of antimicrobial agents and chemotherapy from 1972 to 1998
24. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae
25. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus
26. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus
27. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA
28. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus
29. NorA plasmid resistance to flouroquinolones: Role of copy number and norA frameshift mutations
30. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
31. Characterization of the MexC-MexD-OprJ multidrug efflux system in mutants of Pseudomonas aeruginosa
32. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa
33. Active efflux mechanisms for antimicrobial resistance
34. Role of MexA-MexB-OprM in antibiotic efflux in Pseudomonas aeruginosa
35. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from eastern Europe and North America
36. Classification of beta-lactamases: Groups 1, 2a, 2b, and 2b′
37. Classification of beta-lactamases: Groups 2c, 2d, 2e, 3, and 4
38. β-Lactam resistance amongst Enterobacter species
39. The signal transducer encoded by ampG is essential for induction of chromosomal AmgC β-lactamase in Escherichia coli by β-lactam antibiotics and "unspecified" inducers
40. Inactivation of the ampD gene causes semiconstitutive overproduction of the inducible Citrobacter freundii β-lactamase
41. Altered phenotypes associate with ampD mutations in Enterobacter cloacae
42. Sequencing and analysis of four new Enterobacter ampD alleles
43. The negative regulator of β-lactamase induction AmpD is a N-acetyl-anhydromuramyl-L-alanine amidase
44. Inducible β-lactamases: Clinical and epidemiological implications for use of newer cephalosporins
45. Enterobacter spp.: A pathogen poised to flourish at the turn of the century
46. Prevalence and resistance mechanisms of common bacterial respiratory pathogens
47. R-factor trimethoprim resistance mechanism: An insusceptible target site
48. A new mechanism of plasmid trimethoprim resistance. Characterization of an inducible dihyrofolate reductase
49. Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole
50. Antibiotic resistance in Haemophilus influenzae: Epidemiology, mechanisms, and therapeutic possibilities
51. Emergence of antimicrobial resistance in community-acquired pulmonary pathogens
52. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study
53. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides
54. Drug-resistant pathogens in community- and hospital-acquired pneumonia
55. Antimicrobial resistance in gram-positive bacteria: The myth of the MIC. Minimum inhibitory concentration
56. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit
57. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study
58. The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins
59. Beta-lactam-resistant Streptococcus pneumoniae: Epidemiology and evolutionary mechanism
60. Resistance to antibiotics mediated by target alterations
61. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: Characterization of South African isolates
62. Macrolide resistance phenotypes and genotypes in French clinical isolates of Streptococcus pneumoniae. Observatoire de Normandie du Pneumocoque